274 results on '"Central Nervous System Agents pharmacokinetics"'
Search Results
202. Applications of a blood-brain barrier technology platform to predict CNS penetration of various chemotherapeutic agents. 1. Anti-infective drugs.
- Author
-
Adenot M, Perriere N, Scherrmann JM, and Lahana R
- Subjects
- Animals, Biological Transport, Drug Evaluation, Preclinical, Permeability, Prognosis, Rats, Blood-Brain Barrier metabolism, Central Nervous System metabolism, Central Nervous System Agents pharmacokinetics, Computer Simulation, Models, Biological
- Abstract
Except for a few well-documented CNS therapeutics, quantitative data on blood-brain barrier (BBB) permeation is incomplete, unreliable or nonexistent and this is a major impediment in BBB modeling. Furthermore, only the passive diffusion component is generally taken into account. Three techniques of modeling (in vivo, in vitro and in silico) were set up and compared. The in silico predicted permeation of 287 anti-infective drugs has been faced to clinical observations. Good correlations were observed between in vitro permeability coefficients, influx transfer coefficients from in vivo studies and Pe scores from the computational model. High Pe score values are associated with an increase of reported CNS side effects., (Copyright 2007 S. Karger AG, Basel.)
- Published
- 2007
- Full Text
- View/download PDF
203. Nanobiotechnology-based drug delivery to the central nervous system.
- Author
-
Jain KK
- Subjects
- Animals, Blood-Brain Barrier physiology, Central Nervous System Agents pharmacokinetics, Humans, Central Nervous System metabolism, Drug Delivery Systems, Nanotechnology
- Abstract
Background: Drug delivery across the blood-brain barrier (BBB) is a major limitation in the treatment of central nervous system (CNS) disorders. Several approaches are being investigated to improve drug delivery across the BBB., Objective/methods: This review deals with the role of nanobiotechnology in CNS drug delivery. The small size of the nanoparticles enables them to penetrate the BBB and facilitate the delivery of drugs across the barrier. Several mechanisms are involved in this process and various strategies are used based on different types of nanomaterial and combinations with therapeutic agents. Examples are given of the use of liposomes and polymeric nanoparticles., Results: Nanoparticles can be used as nonviral vectors for CNS gene therapy. Although the use of nanotechnology is expected to reduce the need for invasive procedures for delivery of therapeutics to the CNS, some devices such as implanted catheters and reservoirs will still be needed. Nanomaterials can improve the safety and efficacy of such devices. Nano-engineered probes can deliver drugs at the cellular level using nanofluidic channels. There is some concern about the safety of nanoparticle entry in the brain and this needs to be resolved before human use., Conclusion: Although there is no approved nanotechnology-based CNS drug as yet that incorporates nanobiotechnology, the future for such developments is promising.
- Published
- 2007
- Full Text
- View/download PDF
204. Applications of a blood-brain barrier technology platform to predict CNS penetration of various chemotherapeutic agents. 2. Cationic peptide vectors for brain delivery.
- Author
-
Adenot M, Merida P, and Lahana R
- Subjects
- Amino Acid Sequence, Animals, Biological Transport, Drug Carriers chemistry, Drug Evaluation, Preclinical, Humans, Molecular Sequence Data, Oligopeptides chemistry, Peptide Library, Prognosis, Rats, Blood-Brain Barrier metabolism, Central Nervous System metabolism, Central Nervous System Agents pharmacokinetics, Drug Carriers pharmacokinetics, Models, Biological, Oligopeptides pharmacokinetics
- Abstract
Background: SynB family peptides conjugated to several drugs have been shown to increase the brain uptake and in vivo activities of these drugs via an adsorptive-mediated transcytosis mechanism. Based on both in vivo and in vitro experimental data, a cell uptake component has been added to our computational model of blood-brain barrier., Methods: In situ brain perfusion, in vitro cell model and a computational cell uptake model have been used to discover brain-penetrating properties of SynB peptides and to screen libraries of new rationally designed peptide vectors suitable for brain drug delivery., Results and Conclusion: Starting from small peptide vectors that enhance the brain transport coefficient, the BBB platform has made it possible to design libraries of peptide vectors with enhanced transport properties., (Copyright 2007 S. Karger AG, Basel.)
- Published
- 2007
- Full Text
- View/download PDF
205. Correlation of blood-brain penetration using structural descriptors.
- Author
-
Katritzky AR, Kuanar M, Slavov S, Dobchev DA, Fara DC, Karelson M, Acree WE Jr, Solov'ev VP, and Varnek A
- Subjects
- Algorithms, Animals, Drug Design, Humans, Models, Statistical, Quantitative Structure-Activity Relationship, Software, Blood-Brain Barrier physiology, Central Nervous System Agents chemistry, Central Nervous System Agents pharmacokinetics, Models, Biological
- Abstract
Experimental blood-brain partition coefficients (logBB) for a diverse set of 113 drug molecules are correlated with computed structural descriptors using CODESSA-PRO and ISIDA programs to give statistically significant QSAR models based respectively, on molecular and on fragment descriptors. The linear correlation CODESSA-PRO five-descriptor model has correlation coefficient R2=0.781 and standard deviation s2=0.123. The 'consensus model' of ISIDA gave R2=0.872 and s2=0.047. The developed models were successfully validated using the central nervous system activity data of an external test set of 40 drug molecules.
- Published
- 2006
- Full Text
- View/download PDF
206. Reading and writing the blood-brain barrier: relevance to therapeutics.
- Author
-
Czeisler BM and Janigro D
- Subjects
- Animals, Humans, Osmotic Pressure, Permeability, S100 Proteins blood, Tight Junctions, Blood-Brain Barrier, Central Nervous System Agents pharmacokinetics
- Abstract
The blood-brain barrier (BBB) serves to protect the central nervous system (CNS) from damage by exogenous molecules. In doing so, it also can prevent some drugs from reaching their sites of action. Accordingly, a variety of methods for bypassing the BBB have been developed. Ekwuribe et al. recently patented a method for drug conjugation in order to increase lipophilicity, and therefore BBB permeability. Shalev developed a device for opening the barrier via parasympathetic nerve fiber stimulation and Gudkov et al. produced compounds that modulate the activity of multidrug transporter proteins, by either increasing or decreasing the selective permeability of the BBB. A variety of CNS disorders contribute to barrier disruption, and detection of this opening can be used for both diagnostic purposes and for determining time periods when drugs can more easily enter the CNS. While expensive and time-consuming imaging techniques are currently used for this purpose, Janigro et al. have devised a method for detecting plasma levels of S100beta, a peripheral protein marker for BBB disruption. These techniques for both "reading" and "writing" the BBB will help new and old medications to reach their pharmacological targets in the CNS.
- Published
- 2006
- Full Text
- View/download PDF
207. Application of microdialysis in clinical pharmacology.
- Author
-
Höcht C, Opezzo JA, Bramuglia GF, and Taira CA
- Subjects
- Animals, Antineoplastic Agents pharmacokinetics, Blood Glucose analysis, Central Nervous System Agents pharmacokinetics, Humans, Muscle, Skeletal metabolism, Skin drug effects, Skin metabolism, Sterilization, Microdialysis methods, Pharmacokinetics
- Abstract
Microdialysis has been developed during the last 25 years by several authors primarily to study brain function and changes in levels of endogenous compounds such as neurotransmitters or metabolites in different laboratory animals. However, in the last ten years microdialysis sampling has been introduced as a versatile technique in the clinical setting. Although, microdialysis sampling has been extensively used for metabolic monitoring in patients, it was also employed for the study of distribution of different therapeutic agents especially anti-infective and antineoplasic drugs. In addition, clinical effect of drugs in patients could be also determined by means of microdialysis. So, this article reviewed the vast applications of the microdialysis technique for the study of pharmacokinetic and pharmacodynamic properties of drugs in the clinical setting.
- Published
- 2006
- Full Text
- View/download PDF
208. Pharmacokinetics and tolerability of lamotrigine and olanzapine coadministered to healthy subjects.
- Author
-
Sidhu J, Job S, Bullman J, Francis E, Abbott R, Ascher J, and Theis JG
- Subjects
- Adolescent, Adult, Antidepressive Agents adverse effects, Antidepressive Agents blood, Antidepressive Agents pharmacokinetics, Antipsychotic Agents adverse effects, Antipsychotic Agents blood, Antipsychotic Agents pharmacokinetics, Area Under Curve, Benzodiazepines adverse effects, Benzodiazepines blood, Benzodiazepines pharmacokinetics, Central Nervous System Agents adverse effects, Central Nervous System Agents blood, Drug Administration Schedule, Drug Interactions, Humans, Lamotrigine, Male, Olanzapine, Triazines adverse effects, Triazines blood, Central Nervous System Agents pharmacokinetics, Triazines pharmacokinetics
- Abstract
Aim: To assess the pharmacokinetic effect and tolerability of lamotrigine 200 mg day(-1) and olanzapine 15 mg day(-1) coadministration in healthy male volunteers., Methods: Subjects were randomized to receive either lamotrigine titrated on days 1-42 with olanzapine added on days 43-56 (LTG + OLZ group; N = 16), lamotrigine titration with placebo added on days 43-56 (LTG group; N = 12), or placebo on days 1-42 with olanzapine added on days 43-56 (OLZ group; N = 16). Steady state (0-24 h) pharmacokinetic profiles were determined on day 56 in each group., Results: The average (90% confidence interval) ratios of lamotrigine area under the concentration-time curve from 0 to 24 h and maximum observed concentration for the comparison of LTG + OLZ:LTG were 0.76 (0.65, 0.90) and 0.80 (0.71, 0.90), respectively. Olanzapine pharmacokinetics were essentially unaffected by lamotrigine. The most frequently reported adverse events (AEs) during combination therapy were fatigue, dizziness and mild transaminase elevations. These AEs occurred at similar frequencies in the LTG + OLZ and OLZ cohorts, while being less frequent or absent in the LTG group., Conclusions: Lamotrigine and olanzapine coadministration in patients who may benefit from the combination was supported by this study. Lamotrigine dosing schedules are recommended to remain unchanged when combined with olanzapine therapy. However, the possibility exists that the lamotrigine dose for some patients may need adjustment to optimize treatment when olanzapine is added to or withdrawn from a regimen including lamotrigine.
- Published
- 2006
- Full Text
- View/download PDF
209. Pharmacokinetics of puerarin and ginsenoside Rg1 of CBN injection and the relation with platelet aggregation in rats.
- Author
-
Liu R, Xing D, Lu H, Wu H, and Du L
- Subjects
- Animals, Injections, Male, Rats, Rats, Wistar, Central Nervous System Agents pharmacokinetics, Drugs, Chinese Herbal pharmacokinetics, Ginsenosides pharmacokinetics, Isoflavones pharmacokinetics, Platelet Aggregation drug effects, Vasodilator Agents pharmacokinetics
- Abstract
In order to study the pharmacokinetics of puerarin and ginsenoside Rg1 of cerebral blood nutrition (CBN) and its relationship with pharmacodynamics of platelet aggregation induced by ADP in rat, the blood samples after injection were collected. The concentrations of puerarin and ginsenoside Rg1 in plasma were determined by RP-HPLC, and the platelet aggregations were observed simultaneously. The data showed that there was distinct statistic significance (p < 0.01) for puerarin processing, which was a single compartment model with quick elimination rate (t(1/2beta) = 18 min) and MRT (26 min), while ginsenoside Rg1 processing was a double compartment model with rapid distribution rate (t(1/2alpha) = 8 min), slow elimination rate (t(1/2beta) = 11 hours) and MRT (3.3 hours). Effects of anti-platelet aggregation were presented at 5-10 min, 45-90 min and 6-8 hours after injection separately, and the corresponding concentrations of puerarin were 25-21 microg/ml, 4.5-0.8 microg/ml and 0 microg/ml, ginsenoside Rg1 were 7.6-6.7 microg/ml, 1.2-0.6 microg/ml and 1.8-0.5 microg/ml. The two components presented a positive correlation between their concentrations and the effect of anti-platelet aggregation in 5-10 min after CBN injection (coefficient of correlation were 0.999 and 0.995). However, it was noted that the effect was still stronger even when concentrations of puerarin and ginsenoside Rg1 in plasma decreased. Therefore, puerarin and ginsenoside Rg1 not only had different pharmacokinetics, but also had a positive correlation with platelet aggregation, just in 5-10 min after CBN injection.
- Published
- 2006
- Full Text
- View/download PDF
210. [Direct drug delivery to the brain].
- Author
-
Chekhonin VP, Zhirkov IuA, and Dmitrieva TB
- Subjects
- Biological Transport physiology, Central Nervous System Agents pharmacokinetics, Humans, Blood-Brain Barrier physiology, Brain metabolism, Drug Delivery Systems methods
- Abstract
The authors of the review discuss the present-day state of and promising approaches to directed delivery of biological agents into the brain. Special attention is drawn to micellar and liposomal transport through the blood-brain barrier (BBB) targeted by immunochemical vectors, such as native or hydrophobized antibodies to specific antigens located at the BBB or in the brain parenchyma.
- Published
- 2006
211. Management of lithium toxicity.
- Author
-
Waring WS
- Subjects
- Acute Disease, Central Nervous System Agents pharmacokinetics, Chronic Disease, Humans, Lithium Compounds pharmacokinetics, Poisoning etiology, Poisoning physiopathology, Renal Dialysis, Central Nervous System Agents poisoning, Lithium Compounds poisoning, Poisoning therapy
- Abstract
Lithium salts have been used in the prophylaxis and treatment of depression and bipolar disorder for >50 years. Lithium has a narrow therapeutic range, and several well characterised adverse effects limit the potential usefulness of higher doses. Acute ingestion in lithium-naive patients is generally associated with only short-lived exposure to high concentrations, due to extensive distribution of lithium throughout the total body water compartment. Conversely, chronic toxicity and acute-on-therapeutic ingestion are associated with prolonged exposure to higher tissue concentrations and, therefore, greater toxicity. Lithium toxicity may be life threatening, or result in persistent cognitive and neurological impairment. Therefore, enhanced lithium clearance has been explored as a means of minimising exposure to high tissue concentrations. Although haemodialysis is highly effective in removing circulating lithium, serum concentrations often rebound so repeated or prolonged treatment may be required. Continuous arteriovenous haemodiafiltration and continuous venovenous haemodiafiltration increase lithium clearance, albeit to a lesser extent than haemodialysis, and are more widely accessible. Haemodiafiltration sustained for >16 hours allows effective removal of total body lithium, thereby avoiding rebound effects. Enhanced elimination should be considered in patients at greatest risk of severe poisoning: namely those with chronic or acute-on-therapeutic toxicity, those with clinically significant features, and those with chronic toxicity whose serum lithium concentration is >2.5 mmol/L. The choice between haemodialysis and continuous haemodiafiltration techniques will depend on local accessibility and urgency of enhancing lithium elimination. Further research is required to establish the potential benefits of assisted elimination on clinical outcome in patients with lithium poisoning.
- Published
- 2006
- Full Text
- View/download PDF
212. Toward the prediction of CNS drug-effect profiles in physiological and pathological conditions using microdialysis and mechanism-based pharmacokinetic-pharmacodynamic modeling.
- Author
-
de Lange EC, Ravenstijn PG, Groenendaal D, and van Steeg TJ
- Subjects
- Central Nervous System Agents pharmacology, Humans, Microdialysis methods, Pharmacokinetics, Predictive Value of Tests, Protein Binding physiology, Tissue Distribution physiology, Central Nervous System Agents pharmacokinetics, Microdialysis statistics & numerical data, Models, Biological
- Abstract
Our ultimate goal is to develop mechanism-based pharmacokinetic (PK)-pharmacodynamic (PD) models to characterize and to predict CNS drug responses in both physiologic and pathologic conditions. To this end, it is essential to have information on the biophase pharmacokinetics, because these may significantly differ from plasma pharmacokinetics. It is anticipated that biophase kinetics of CNS drugs are strongly influenced by transport across the blood-brain barrier (BBB). The special role of microdialysis in PK/PD modeling of CNS drugs lies in the fact that it enables the determination of free-drug concentrations as a function of time in plasma and in extracellular fluid of the brain, thereby providing important data to determine BBB transport characteristics of drugs. Also, the concentrations of (potential) extracellular biomarkers of drug effects or disease can be monitored with this technique. Here we describe our studies including microdialysis on the following: (1) the evaluation of the free drug hypothesis; (2) the role of BBB transport on the central effects of opioids; (3) changes in BBB transport and biophase equilibration of anti-epileptic drugs; and (4) the relation among neurodegeneration, BBB transport, and drug effects in Parkinson's disease progression.
- Published
- 2005
- Full Text
- View/download PDF
213. Medicinal chemical properties of successful central nervous system drugs.
- Author
-
Pajouhesh H and Lenz GR
- Subjects
- Animals, Humans, Blood-Brain Barrier physiology, Central Nervous System Agents chemistry, Central Nervous System Agents pharmacokinetics, Drug Design
- Abstract
Fundamental physiochemical features of CNS drugs are related to their ability to penetrate the blood-brain barrier affinity and exhibit CNS activity. Factors relevant to the success of CNS drugs are reviewed. CNS drugs show values of molecular weight, lipophilicity, and hydrogen bond donor and acceptor that in general have a smaller range than general therapeutics. Pharmacokinetic properties can be manipulated by the medicinal chemist to a significant extent. The solubility, permeability, metabolic stability, protein binding, and human ether-ago-go-related gene inhibition of CNS compounds need to be optimized simultaneously with potency, selectivity, and other biological parameters. The balance between optimizing the physiochemical and pharmacokinetic properties to make the best compromises in properties is critical for designing new drugs likely to penetrate the blood brain barrier and affect relevant biological systems. This review is intended as a guide to designing CNS therapeutic agents with better drug-like properties.
- Published
- 2005
- Full Text
- View/download PDF
214. Translational research in central nervous system drug discovery.
- Author
-
Hurko O and Ryan JL
- Subjects
- Animals, Central Nervous System Agents pharmacokinetics, Central Nervous System Diseases physiopathology, Humans, Central Nervous System Agents therapeutic use, Central Nervous System Diseases drug therapy, Drug Design, Drug Evaluation, Preclinical methods, Technology, Pharmaceutical methods
- Abstract
Of all the therapeutic areas, diseases of the CNS provide the biggest challenges to translational research in this era of increased productivity and novel targets. Risk reduction by translational research incorporates the "learn" phase of the "learn and confirm" paradigm proposed over a decade ago. Like traditional drug discovery in vitro and in laboratory animals, it precedes the traditional phase 1-3 studies of drug development. The focus is on ameliorating the current failure rate in phase 2 and the delays resulting from suboptimal choices in four key areas: initial test subjects, dosing, sensitive and early detection of therapeutic effect, and recognition of differences between animal models and human disease. Implementation of new technologies is the key to success in this emerging endeavor.
- Published
- 2005
- Full Text
- View/download PDF
215. Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery.
- Author
-
Alavijeh MS, Chishty M, Qaiser MZ, and Palmer AM
- Subjects
- Animals, Biological Transport physiology, Central Nervous System Agents chemistry, Central Nervous System Agents metabolism, Female, Humans, Male, Blood-Brain Barrier physiology, Central Nervous System Agents pharmacokinetics, Drug Design
- Abstract
The worldwide market for therapies for CNS disorders is worth more than 50 billion dollars and is set to grow substantially in the years ahead. This is because: 1) the incidence of many CNS disorders (e.g., Alzheimer's disease, stroke, and Parkinson's disease) increase exponentially after age 65 and 2) the number of people in the world over 65 is about to increase sharply because of a marked rise in fertility after World War II. However, CNS research and development are associated with significant challenges: it takes longer to get a CNS drug to market (12-16 years) compared with a non-CNS drug (10-12 years) and there is a higher attrition rate for CNS drug candidates than for non-CNS drug candidates. This is attributable to a variety of factors, including the complexity of the brain, the liability of CNS drugs to cause CNS side effects, and the requirement of CNS drugs to cross the blood-brain barrier (BBB). This review focuses on BBB penetration, along with pharmacokinetics and drug metabolism, in the process of the discovery and development of safe and effective medicines for CNS disorders.
- Published
- 2005
- Full Text
- View/download PDF
216. Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans.
- Author
-
Brunner M, Langer O, Sunder-Plassmann R, Dobrozemsky G, Müller U, Wadsak W, Krcal A, Karch R, Mannhalter C, Dudczak R, Kletter K, Steiner I, Baumgartner C, and Müller M
- Subjects
- Adult, Area Under Curve, Carbon Radioisotopes administration & dosage, Carbon Radioisotopes pharmacokinetics, Case-Control Studies, Central Nervous System Agents administration & dosage, Double-Blind Method, Haplotypes, Humans, Injections, Intravenous, Male, Positron-Emission Tomography, Tissue Distribution, Verapamil administration & dosage, Central Nervous System metabolism, Central Nervous System Agents pharmacokinetics, Genes, MDR, Verapamil pharmacokinetics
- Abstract
Background and Objective: Single nucleotide polymorphisms in the human multidrug-resistance gene ABCB1 have been reported to be associated with altered expression and function of P-glycoprotein, an efflux transporter, expressed at the blood-brain barrier. To test whether certain ABCB1 haplotypes contribute to interindividual differences in central nervous system drug distribution, brain distribution of a model P-glycoprotein substrate, the calcium channel inhibitor verapamil, was measured by positron emission tomography (PET) in 2 groups of healthy volunteers., Methods: Ten homozygous carriers (cases) of the TTT haplotype (3435T, 1236T, and 2677T) and 10 controls homozygous for the wild-type CGC haplotype (3435C, 2677G, and 1236C) were administered a mean intravenous bolus of 412 +/- 114 MBq carbon 11-labeled verapamil containing less than 15 nmol of unlabeled verapamil. PET imaging of brain tissue and venous blood sampling were performed for 1 hour after dosing., Results: As a measure of brain penetration, the ratio of PET area under the time-radioactivity curve (AUC) to plasma AUC was calculated from time-radioactivity curves, with a mean ratio of 1.1 +/- 0.3 (SD) (95% confidence interval, 0.9-1.3) for cases and 1.1 +/- 0.2 (95% confidence interval, 0.9-1.2) for controls, respectively (P = .96). Mean brain AUC values were 31.2 +/- 3.9 and 35.7 +/- 5.7 for the TTT and CGC haplotype, respectively (P = .11). Plasma AUCs were not significantly different., Conclusion: No difference in the brain distribution of [(11)C]verapamil could be detected in healthy volunteers differing in ABCB1 haplotypes.
- Published
- 2005
- Full Text
- View/download PDF
217. Drug-drug interactions in older adults: which ones matter?
- Author
-
Hanlon JT and Schmader KE
- Subjects
- Aged, Anti-Arrhythmia Agents adverse effects, Anti-Arrhythmia Agents pharmacokinetics, Anticonvulsants adverse effects, Anticonvulsants pharmacokinetics, Central Nervous System Agents adverse effects, Central Nervous System Agents pharmacokinetics, Humans, Liver metabolism, Polypharmacy, Drug Interactions, Drug-Related Side Effects and Adverse Reactions, Pharmacokinetics, Pharmacology
- Published
- 2005
- Full Text
- View/download PDF
218. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases.
- Author
-
Löscher W and Potschka H
- Subjects
- Animals, Central Nervous System Agents pharmacokinetics, Central Nervous System Agents therapeutic use, Humans, Membrane Transport Proteins chemistry, Mice, Xenobiotics metabolism, Xenobiotics pharmacokinetics, Blood-Brain Barrier physiology, Brain physiology, Brain Diseases drug therapy, Central Nervous System Agents metabolism, Membrane Transport Proteins physiology
- Abstract
The blood-brain barrier (BBB) serves as a protective mechanism for the brain by preventing entry of potentially harmful substances from free access to the central nervous system (CNS). Tight junctions present between the brain microvessel endothelial cells form a diffusion barrier, which selectively excludes most blood-borne substances from entering the brain. Astrocytic end-feet tightly ensheath the vessel wall and appear to be critical for the induction and maintenance of the barrier properties of the brain capillary endothelial cells. Because of these properties, the BBB only allows entry of lipophilic compounds with low molecular weights by passive diffusion. However, many lipophilic drugs show negligible brain uptake. They are substrates for drug efflux transporters such as P-glycoprotein (Pgp), multidrug resistance proteins (MRPs) or organic anion transporting polypeptides (OATPs) that are expressed at brain capillary endothelial cells and/or astrocytic end-feet and are key elements of the molecular machinery that confers the special permeability properties to the BBB. The combined action of these carrier systems results in rapid efflux of xenobiotics from the CNS. The objective of this review is to summarize transporter characteristics (cellular localization, specificity, regulation, and potential inhibition) for drug efflux transport systems identified in the BBB and blood-cerebrospinal fluid (CSF) barrier. A variety of experimental approaches available to ascertain or predict the impact of efflux transport on brain access of therapeutic drugs also are described and critically discussed. The potential impact of efflux transport on the pharmacodynamics of agents acting in the CNS is illustrated. Furthermore, the current knowledge about drug efflux transporters as a major determinant of multidrug resistance of brain diseases such as epilepsy is reviewed. Finally, we summarize strategies for modulating or by-passing drug efflux transporters at the BBB as novel therapeutic approaches to drug-resistant brain diseases.
- Published
- 2005
- Full Text
- View/download PDF
219. Positron emission tomography and single-photon emission computed tomography in central nervous system drug development.
- Author
-
Brooks DJ
- Subjects
- Animals, Central Nervous System Agents pharmacokinetics, Disease Progression, Dose-Response Relationship, Drug, Humans, Nervous System Diseases pathology, Neurodegenerative Diseases diagnostic imaging, Central Nervous System Agents therapeutic use, Nervous System Diseases diagnostic imaging, Nervous System Diseases drug therapy, Positron-Emission Tomography, Tomography, Emission-Computed, Single-Photon
- Abstract
In this review, the value of functional imaging [positron emission tomography (PET)/single-photon emission computed tomography (SPECT)] in drug development is considered. Radionuclide imaging can help establish the diagnosis of neurodegenerative disorders where this is in doubt and provides a potential biomarker for following drug effects on disease progression. PET and SPECT can help understand mechanisms of disease and determine the functional effects of therapeutic approaches on neurotransmission and metabolism. Synthesizing radiotracer analogs of novel drugs can provide proof of principle that these agents reach their enzyme or receptor targets and delineate their regional brain distribution. If such radiotracers do not prove to have ideal properties for imaging, the concept of microdosing potentially allows multiple other drug analogs to be tested with less stringent regulatory requirements than for novel medicinals. Finally, PET tracers can provide receptor and enzyme active site dose occupancy profiles, thereby guiding dosage selection for phase 1 and phase 2 trials. The eventual hope is that radiotracer imaging will provide a surrogate marker for drug efficacy, although this has yet to be realized, and progress the concept of personalized medicine where receptor/enzyme binding profiles help predict therapeutic outcome.
- Published
- 2005
- Full Text
- View/download PDF
220. Modelling a spontaneously reported side effect by use of a Markov mixed-effects model.
- Author
-
Zingmark PH, Kågedal M, and Karlsson MO
- Subjects
- Adult, Algorithms, Central Nervous System Agents administration & dosage, Central Nervous System Agents pharmacokinetics, Cross-Over Studies, Double-Blind Method, Humans, Infusions, Intravenous, Male, Pharmacokinetics, Software, Drug-Related Side Effects and Adverse Reactions, Markov Chains, Models, Statistical
- Abstract
Aims: To present a method for analyzing side-effect data where change in severity is spontaneously reported during the experiment., Methods: A clinical study in 12 healthy volunteers aimed to investigate the concentration-response characteristics of a CNS-specific side-effect was conducted. After an open session where the subjects experienced the side-effect and where the individual pharmacokinetic parameters were evaluated they were randomized to a sequence of three different infusion rates of the drug in a double-blinded crossover way. The infusion rates were individualized to achieve the same target concentration in all subjects and different drug input rates were selected to mimic absorption profiles from different formulations. The occurrence of the specific side-effect and any subsequent change in severity was self-reported by the subjects. Severity was recorded as 0 = no side-effect, 1 = mild side-effect and 2 = moderate or severe side-effect., Results: The side-effect data were analyzed using a mixed-effects model for ordered categorical data with and without Markov elements. The former model estimated the probability of having a certain side-effect score conditioned on the preceding observation and drug exposure. The observed numbers of transitions between scores were from 0 -> 1: 24, from 0- > 2: 11, from 1 - >, 2: 23, from 2- > 1: 1, from 2- > 0: 32 and from 1 - >0: 2. The side-effect model consisted of an effect-compartment model with a tolerance compartment. The predictive performance of the Markov model was investigated by a posterior predictive check (PPC), where 100 datasets were simulated from the final model. Average number of the different transitions from the PPC was from 0 - > 1: 26, from 0 - > 2: 11, from 1 - > 2: 25, from 2 - >1: 1, from 2 - >0: 35 and from 1 - > 0: 1. A similar PPC for the model without Markov elements was at considerable disparity with the data., Conclusion: This approach of incorporating Markov elements in an analysis of spontaneously reported categorical side-effect data could adequately predict the observed side-effect time course and could be considered in analyses of categorical data where dependence between observations is an issue.
- Published
- 2005
- Full Text
- View/download PDF
221. Herb-drug interactions: an overview of the clinical evidence.
- Author
-
Izzo AA
- Subjects
- Anti-Allergic Agents pharmacokinetics, Anti-Allergic Agents pharmacology, Anti-Asthmatic Agents pharmacokinetics, Anti-Asthmatic Agents pharmacology, Anti-Infective Agents pharmacokinetics, Anti-Infective Agents pharmacology, Cardiovascular Agents pharmacokinetics, Cardiovascular Agents pharmacology, Central Nervous System Agents pharmacokinetics, Central Nervous System Agents pharmacology, Clinical Trials as Topic, Contraceptives, Oral pharmacokinetics, Contraceptives, Oral pharmacology, Humans, Hypoglycemic Agents pharmacokinetics, Hypoglycemic Agents pharmacology, Immunosuppressive Agents pharmacokinetics, Immunosuppressive Agents pharmacology, Herb-Drug Interactions
- Abstract
Herbal medicines are mixtures of more than one active ingredient. The multitude of pharmacologically active compounds obviously increases the likelihood of interactions taking place. Hence, the likelihood of herb-drug interactions is theoretically higher than drug-drug interactions, if only because synthetic drugs usually contain single chemical entities. Case reports and clinical studies have highlighted the existence of a number of clinically important interactions, although cause-and-effect relationships have not always been established. Herbs and drugs may interact either pharmacokinetically or pharmacodynamically. Through induction of cytochrome P450 enzymes and/or P-glycoprotein, some herbal products (e.g. St John's wort) have been shown to lower the plasma concentration (and/or the pharmacological effect) of a number of conventional drugs, including cyclosporine, indinavir, irinotecan, nevirapine, oral contraceptives and digoxin. The majority of such interactions involves medicines that require regular monitoring of blood levels. To date there is less evidence relating to the pharmacodynamic interaction. However, for many of the interactions discussed here, the understanding of the mechanisms involved is incomplete. Taking herbal agents may represent a potential risk to patients under conventional pharmacotherapy.
- Published
- 2005
- Full Text
- View/download PDF
222. Development of neuropeptide drugs that cross the blood-brain barrier.
- Author
-
Egleton RD and Davis TP
- Subjects
- Animals, Biological Availability, Biological Transport, Active physiology, Brain Chemistry, Glycosylation, Humans, Blood-Brain Barrier physiology, Central Nervous System Agents pharmacokinetics, Neuropeptides pharmacokinetics
- Abstract
In recent years, there have been several important advancements in the development of neuropeptide therapeutics. Nevertheless, the targeting of peptide drugs to the CNS remains a formidable obstacle. Delivery of peptide drugs is limited by their poor bioavailability to the brain due to low metabolic stability, high clearance by the liver, and the presence of the blood brain barrier (BBB). Multiple strategies have been devised in an attempt to improve peptide drug delivery to the brain, with variable results. In this review, we discuss several of the strategies that have been used to improve both bioavailability and BBB transport, with an emphasis on antibody based vector delivery, useful for large peptides/small proteins, and glycosylation, useful for small peptides. Further development of these delivery methods may finally enable peptide drugs to be useful for the treatment of neurological disease states.
- Published
- 2005
- Full Text
- View/download PDF
223. The blood-brain barrier and neurotherapeutics.
- Author
-
Pardridge WM
- Subjects
- Brain Chemistry physiology, Carrier Proteins metabolism, Humans, Molecular Weight, Blood-Brain Barrier physiology, Central Nervous System Agents pharmacokinetics, Central Nervous System Agents therapeutic use, Nervous System Diseases drug therapy, Nervous System Diseases metabolism
- Published
- 2005
- Full Text
- View/download PDF
224. The blood-brain barrier: bottleneck in brain drug development.
- Author
-
Pardridge WM
- Subjects
- Administration, Intranasal, Animals, Blood-Brain Barrier drug effects, Carrier Proteins metabolism, Central Nervous System Agents administration & dosage, Drug Delivery Systems, Drug Design, Humans, Hydrogen Bonding, Molecular Weight, Blood-Brain Barrier physiology, Central Nervous System Agents pharmacokinetics, Central Nervous System Agents pharmacology
- Abstract
The blood-brain barrier (BBB) is formed by the brain capillary endothelium and excludes from the brain approximately 100% of large-molecule neurotherapeutics and more than 98% of all small-molecule drugs. Despite the importance of the BBB to the neurotherapeutics mission, the BBB receives insufficient attention in either academic neuroscience or industry programs. The combination of so little effort in developing solutions to the BBB problem, and the minimal BBB transport of the majority of all potential CNS drugs, leads predictably to the present situation in neurotherapeutics, which is that there are few effective treatments for the majority of CNS disorders. This situation can be reversed by an accelerated effort to develop a knowledge base in the fundamental transport properties of the BBB, and the molecular and cellular biology of the brain capillary endothelium. This provides the platform for CNS drug delivery programs, which should be developed in parallel with traditional CNS drug discovery efforts in the molecular neurosciences.
- Published
- 2005
- Full Text
- View/download PDF
225. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities.
- Author
-
Begley DJ
- Subjects
- Animals, Blood-Brain Barrier drug effects, Blood-Brain Barrier metabolism, Central Nervous System metabolism, Central Nervous System Agents pharmacokinetics, Central Nervous System Diseases metabolism, Genetic Therapy methods, Humans, Liposomes, Nanostructures, Central Nervous System drug effects, Central Nervous System Agents administration & dosage, Central Nervous System Diseases drug therapy, Drug Delivery Systems methods
- Abstract
The presence of a blood-brain barrier (BBB) and a blood-cerebrospinal fluid barrier presents a huge challenge for effective delivery of therapeutics to the central nervous system (CNS). Many potential drugs, which are effective at their site of action, have failed and have been discarded during their development for clinical use due to a failure to deliver them in sufficient quantity to the CNS. In consequence, many diseases of the CNS are undertreated. In recent years, it has become clear that the blood-CNS barriers are not only anatomical barriers to the free movement of solutes between blood and brain but also transport and metabolic barriers. The cell association, sometimes called the neurovascular unit, constitutes the BBB and is now appreciated to be a complex group of interacting cells, which in combination induce the formation of a BBB. The various strategies available and under development for enhancing drug delivery to the CNS are reviewed.
- Published
- 2004
- Full Text
- View/download PDF
226. New aspects of the blood-brain barrier transporters; its physiological roles in the central nervous system.
- Author
-
Ohtsuki S
- Subjects
- Amino Acids, Acidic metabolism, Animals, Biological Transport physiology, Brain blood supply, Carrier Proteins metabolism, Central Nervous System Agents pharmacokinetics, Creatine metabolism, Endothelial Cells metabolism, Humans, Neurotransmitter Agents metabolism, Blood-Brain Barrier metabolism, Brain metabolism
- Abstract
The blood-brain barrier (BBB) segregates the circulating blood from interstitial fluid in the brain, and restricts drug permeability into the brain. Our latest studies have revealed that the BBB transporters play important physiological roles in maintaining the brain milieu. The BBB supplies creatine to the brain for an energy-storing system, and creatine transporter localized at the brain capillary endothelial cells (BCECs) is involved in BBB creatine transport. The BBB is involved in the brain-to-blood efflux transport of the suppressive neurotransmitter, gamma-aminobutyric acid, and GAT2/BGT-1 mediates this transport process. BCECs also express serotonin and norepinephrine transporters. Organic anion transporter 3 (OAT3) and ASCT2 are localized at the abluminal membrane of the BCECs. OAT3 is involved in the brain-to-blood efflux of a dopamine metabolite, a uremic toxin and thiopurine nucleobase analogs. ASCT2 plays a role in L-isomer-selective aspartic acid efflux transport at the BBB. Dehydroepiandrosterone sulfate and small neutral amino acids undergo brain-to-blood efflux transport mediated by organic anion transporting polypeptide 2 and ATA2, respectively. The BBB transporters are regulated by various factors, ATA2 by osmolarity, taurine transporter by TNF-alpha, and L-cystine/L-glutamic acid exchange transporter by oxidative stress. Clarifying the physiological roles of BBB transport systems should give us important information allowing the development of better CNS drugs and improving our understanding of the relationship between CNS disorders and BBB function.
- Published
- 2004
- Full Text
- View/download PDF
227. When breastfeeding mothers need CNS-acting drugs.
- Author
-
Rubin ET, Lee A, and Ito S
- Subjects
- Anticonvulsants administration & dosage, Anticonvulsants adverse effects, Anticonvulsants pharmacokinetics, Antidepressive Agents administration & dosage, Antidepressive Agents adverse effects, Antidepressive Agents pharmacokinetics, Antipsychotic Agents administration & dosage, Antipsychotic Agents adverse effects, Antipsychotic Agents pharmacokinetics, Central Nervous System Agents administration & dosage, Female, Humans, Infant, Infant, Newborn, Breast Feeding, Central Nervous System Agents adverse effects, Central Nervous System Agents pharmacokinetics, Milk, Human metabolism
- Abstract
Background: Breastfeeding is the ideal method of infant nutrition. However, if mothers need medications such as the central nervous system (CNS) acting drugs, infant safety concerns arise. Summarized information on infant exposure levels to drugs in milk and associated side effect profiles will help clinicians to rationalize and justify important drug therapy for a breastfeeding patient., Methods: Electronic searches of MEDLINE and PsycINFO from 1966-2003, and of EMBASE from 1980-2003, were conducted for studies on breastfeeding or breast milk and medications in the following categories: antidepressants, antipsychotics, antiepileptics (or anticonvulsants) and anxiolytics. The infant exposure level (%) was defined as follows: [Drug concentration in milk (mg/mL)] x [Daily milk intake (mL/kg/d)] x 100 / Maternal dose (mg/kg/d)., Results: A total of 129 papers were eligible for analyses. Our findings indicate that the majority of the CNS-acting drugs, if taken by nursing women, result in average exposure levels to their breast-fed infants of less than 10% of the therapeutic doses per kg body weight. Exceptions are lithium, ethosuximide, phenobarbital, primidone, lamotrigine and topiramate. Adverse effect profiles do not always correlate with a higher exposure level. Overall, most reported adverse effect profiles appear benign. Where adverse effects were reported, they were often confounded by intrauterine exposure., Conclusions: CNS-acting drugs taken by the mother do not appear to pose any major risks of immediate adverse effects to the breastfeeding infant, although with most of the newer drugs further research is needed to be conclusive.
- Published
- 2004
228. Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain.
- Author
-
Kreuter J
- Subjects
- Antineoplastic Agents administration & dosage, Antineoplastic Agents chemistry, Antineoplastic Agents pharmacokinetics, Blood-Brain Barrier chemistry, Brain drug effects, Brain Neoplasms drug therapy, Central Nervous System Agents pharmacokinetics, Humans, Surface Properties, Blood-Brain Barrier metabolism, Brain metabolism, Central Nervous System Agents administration & dosage, Central Nervous System Agents chemistry, Drug Carriers chemistry, Drug Delivery Systems methods, Nanostructures chemistry
- Abstract
Poly(alkyl cyanoacrylate) nanoparticles enable the delivery of a number of drugs, including doxorubicin, loperamide, tubocurarine, the NMDA receptor antagonist MRZ 2/576, and the peptides dalargin and kytorphin across the blood-brain barrier (BBB) after coating with surfactants. However, only the surfactants polysorbate (Tween) 20, 40, 60 and 80, and some poloxamers (Pluronic F 68) can induce this uptake. The mechanism for the delivery across the BBB most likely is endocytosis via the LDL receptor by the endothelial cells lining the brain blood capillaries after injection of the nanoparticles into the blood stream. This endocytotic uptake seems to be mediated by the adsorption of apolipoprotein B and/or E adsorption from the blood. Thus, the nanoparticles could mimic lipoprotein particles and act as "Trojan Horses." The drug, then, may be released either within these cells followed by passive diffusion into the brain or be transported into the brain by transcytosis.
- Published
- 2004
- Full Text
- View/download PDF
229. Hyperhomocysteinaemia in treated patients with Huntington's disease homocysteine in HD.
- Author
-
Andrich J, Saft C, Arz A, Schneider B, Agelink MW, Kraus PH, Kuhn W, and Müller T
- Subjects
- Adult, Biomarkers blood, Central Nervous System Agents adverse effects, Central Nervous System Agents pharmacokinetics, Disease Progression, Drug Interactions, Female, Humans, Huntingtin Protein, Huntington Disease blood, Huntington Disease diagnosis, Hyperhomocysteinemia diagnosis, Male, Metabolic Clearance Rate drug effects, Middle Aged, Mutation genetics, Nerve Tissue Proteins genetics, Neurologic Examination, Nuclear Proteins genetics, Central Nervous System Agents administration & dosage, Homocysteine blood, Huntington Disease drug therapy, Hyperhomocysteinemia blood
- Abstract
Significantly increased plasma total homocysteine levels (t-Hcys) appeared in treated Huntington disease (HD) patients compared to controls and untreated HD subjects. Because the protein Huntingtin interacts with the homocysteine metabolism modulating enzyme cystathionine beta-synthase, we hypothesize that homocysteine promotes neurodegeneration in HD.
- Published
- 2004
- Full Text
- View/download PDF
230. Blood-brain barrier permeation models: discriminating between potential CNS and non-CNS drugs including P-glycoprotein substrates.
- Author
-
Adenot M and Lahana R
- Subjects
- Central Nervous System Agents pharmacokinetics, ATP Binding Cassette Transporter, Subfamily B metabolism, Blood-Brain Barrier, Central Nervous System drug effects, Central Nervous System Agents pharmacology, Models, Biological
- Abstract
The aim of this article is to present the design of a large heterogeneous CNS library (approximately 1700 compounds) from WDI and mapping CNS drugs using QSAR models of blood-brain barrier (BBB) permeation and P-gp substrates. The CNS library finally includes 1336 BBB-crossing drugs (BBB+), 259 molecules non-BBB-crossing (BBB-), and 91 P-gp substrates (either BBB+ or BBB-). Discriminant analysis and PLS-DA have been used to model the passive diffusion component of BBB permeation and potential physicochemical requirement of P-gp substrates. Three categories of explanatory variables (Cdiff, BBBpred, PGPpred) have been suggested to express the level of permeation within a continuous scale, starting from two classes data (BBB+/BBB-), allowing that the degree to which each compound belongs to an activity class is given using a membership score. Finally, statistical data analyses have shown that some very simple descriptors are sufficient to evaluate BBB permeation in most cases, with a high rate of well-classified drugs. Moreover, a "CNS drugs" map, including P-gp substrates and accurately reflecting the in vivo behavior of drugs, is proposed as a tool for CNS drug virtual screening.
- Published
- 2004
- Full Text
- View/download PDF
231. Effects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers.
- Author
-
Skarke C, Jarrar M, Schmidt H, Kauert G, Langer M, Geisslinger G, and Lötsch J
- Subjects
- Administration, Oral, Alleles, Base Sequence, Central Nervous System Agents pharmacokinetics, Double-Blind Method, Drug Interactions, Drug Resistance, Multiple, Genetic Variation, Haplotypes, Heterozygote, Humans, Loperamide pharmacokinetics, Miosis chemically induced, Narcotics pharmacokinetics, Quinidine blood, Central Nervous System drug effects, Central Nervous System Agents pharmacology, Genes, MDR, Loperamide pharmacology, Mutation, Narcotics pharmacology, Pupil drug effects, Quinidine pharmacology
- Abstract
Objective: Mutations in the ABCB1 gene have been associated with decreased expression and net function of P-glycoprotein (P-gp). We investigated the modulation of the central nervous effects of loperamide resulting from ABCB1 genetic variants., Methods: On two occasions, 20 healthy volunteers received 24 mg loperamide suspension orally and, in a double-blind randomized two-way crossover fashion, 800 mg quinidine or placebo orally 1 h before loperamide. Pupil size was measured for 5 h following loperamide administration, and plasma concentrations of loperamide and quinidine were measured for 6 h. Single nucleotide polymorphisms and haplotypes including G2677T(A) (exon 21) and C3435T (exon 26) were analysed for their relation to plasma concentrations of quinidine and loperamide and to the miotic effects of loperamide., Results: Loperamide plasma concentrations with quinidine co-administration were about twice as high as those without quinidine. The ABCB1 haplotype G2677/T3435 was associated with the highest loperamide plasma concentrations, which were about 1.5 times higher than in non-carriers of this haplotype. Plasma concentrations of quinidine did not differ among carriers and non-carriers of genetic variants. When quinidine was co-administered with loperamide, pupil size decreased. Without quinidine it changed only minimally. The ABCB1 TT3435 genotype was associated with the most pronounced increase of the miotic effects of loperamide when quinidine was co-administered. This was accompanied by a tendency toward higher plasma loperamide in TT3435 carriers., Conclusions: Our data support a functional importance of the ABCB1 mutations for plasma concentrations and central nervous actions of the opioid loperamide., (Copyright 2003 Lippincott Williams & Wilkins)
- Published
- 2003
- Full Text
- View/download PDF
232. The blood-brain barrier choline transporter as a brain drug delivery vector.
- Author
-
Allen DD and Lockman PR
- Subjects
- Animals, Biological Transport, Active physiology, Central Nervous System Agents pharmacokinetics, Humans, Blood-Brain Barrier physiology, Brain metabolism, Choline metabolism, Drug Delivery Systems, Membrane Transport Proteins metabolism
- Abstract
Choline is a ubiquitous molecule, found throughout almost every tissue in the body. Given it is a charged cation, nearly every cellular membrane has a transport mechanism to meet the intracellular and membrane need for choline. The blood-brain barrier is no exception in that a carrier-mediated transport mechanism is present to deliver choline from plasma to brain. The carrier consists of an anionic binding area that attracts positively charged quaternary ammonium groups or simple cations. Recent reports have shown this vector to be efficacious in delivering quaternary ammonium analogs of nicotine to brain. Future work is being completed to determine if other cationic or positively charged therapeutics can be effectively delivered to brain via this carrier.
- Published
- 2003
- Full Text
- View/download PDF
233. The potential of antisense as a CNS therapeutic.
- Author
-
Godfray J and Estibeiro P
- Subjects
- Alzheimer Disease drug therapy, Biodegradation, Environmental, Brain Neoplasms drug therapy, Central Nervous System Agents administration & dosage, Central Nervous System Agents pharmacokinetics, Central Nervous System Agents pharmacology, Central Nervous System Diseases drug therapy, Drug Delivery Systems, Drug Design, Gene Silencing, Humans, Liposomes administration & dosage, Mental Disorders drug therapy, Molecular Structure, Oligonucleotides, Antisense administration & dosage, Oligonucleotides, Antisense chemistry, Oligonucleotides, Antisense pharmacokinetics, Oligonucleotides, Antisense pharmacology, Oxidative Stress, Pharmaceutical Vehicles, Polymers administration & dosage, Structure-Activity Relationship, Central Nervous System Agents therapeutic use, Oligonucleotides, Antisense therapeutic use
- Abstract
Antisense offers a precise and specific means of knocking down expression of a target gene, and is a major focus of research in neuroscience and other areas. It has application as a tool in gene function and target validation studies and is emerging as a therapeutic technology in its own right. It has become increasingly obvious, however, that there are a number of hurdles to overcome before antisense can be used effectively in the CNS, most notably finding suitable nucleic acid chemistries and an effective delivery vehicle to transport antisense oligonucleotides (AS-ODNs) across the blood-brain barrier (BBB) to their site of action. Despite these problems, a number of potential applications of AS-ODNs in CNS therapeutics have been validated in vitro and, in some cases, in vivo. Here the authors outline available nucleic acid chemistries and review progress in the development of non-invasive delivery vehicles that may be applicable to CNS therapeutics. Further to this, they discuss a number of experimental applications of AS-ODNs to CNS research and speculate on the development of antisense techniques to treat CNS disease.
- Published
- 2003
- Full Text
- View/download PDF
234. The Challenges of CNS Drug Discovery. 4 March 2003, GlaxoSmithKline plc, Harlow, UK.
- Author
-
Norman P
- Subjects
- Blood-Air Barrier drug effects, Brain drug effects, Central Nervous System Agents pharmacokinetics, Computer Simulation, Diagnostic Imaging, Humans, Receptors, Glycine antagonists & inhibitors, Receptors, Metabotropic Glutamate antagonists & inhibitors, Receptors, Serotonin drug effects, Serotonin Antagonists pharmacology, Central Nervous System Agents pharmacology, Pharmacology
- Published
- 2003
235. [Breaking down barriers--about the art of escorting drugs into the brain].
- Author
-
Kahl U
- Subjects
- Animals, Central Nervous System Agents metabolism, Humans, Nanotechnology, Blood-Brain Barrier, Brain metabolism, Central Nervous System Agents pharmacokinetics, Drug Carriers, Drug Delivery Systems
- Published
- 2003
236. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
- Author
-
Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, and Polli JW
- Subjects
- Animals, Blood-Brain Barrier physiology, Cell Line, Central Nervous System Agents pharmacology, Dogs, Drug Delivery Systems methods, Permeability drug effects, Pharmaceutical Preparations metabolism, ATP Binding Cassette Transporter, Subfamily B, Member 1 physiology, Blood-Brain Barrier drug effects, Cell Membrane Permeability drug effects, Central Nervous System Agents pharmacokinetics
- Abstract
Membrane permeability and P-glycoprotein (Pgp) can be limiting factors for blood-brain barrier penetration. The objectives of this study were to determine whether there are differences in the in vitro permeability, Pgp substrate profiles, and physicochemical properties of drugs for central nervous system (CNS) and non-CNS indications, and whether these differences are useful criteria in selecting compounds for drug development. Apparent permeability (P(app)) and Pgp substrate profiles for 93 CNS (n = 48) and non-CNS (n = 45) drugs were determined by monolayer efflux. Calcein-AM inhibition assays were used to supplement the efflux results. The CNS set (2 of 48, 4.2%) had a 7-fold lower incidence of passive permeability values <150 nm/s compared with the non-CNS set (13 of 45, 28.9%). The majority of drugs (72.0%, 67 of 93) were not Pgp substrates; however, 49.5% (46 of 93) were positive in the calcein-AM assay when tested at 100 microM. The CNS drug set (n = 7 of 48, 14.6%) had a 3-fold lower incidence of Pgp-mediated efflux than the non-CNS drug set (n = 19 of 45, 42.2%). Analysis of 18 physicochemical properties revealed that the CNS drug set had fewer hydrogen bond donors, fewer positive charges, greater lipophilicity, lower polar surface area, and reduced flexibility compared with the non-CNS group (p < 0.05), properties that enhance membrane permeability. This study on a large, diverse set of marketed compounds clearly demonstrates that permeability, Pgp-mediated efflux, and certain physicochemical properties are factors that differentiate CNS and non-CNS drugs. For CNS delivery, a drug should ideally have an in vitro passive permeability >150 nm/s and not be a good (B --> A/A --> B ratio <2.5) Pgp substrate.
- Published
- 2002
- Full Text
- View/download PDF
237. Cerebrospinal fluid concentrations of atracurium, laudanosine and vecuronium following clinical subarachnoid hemorrhage.
- Author
-
Tassonyi E, Fathi M, Hughes GJ, Chiodini F, Bertrand D, Muller D, and Fuchs-Buder T
- Subjects
- Adolescent, Adult, Aged, Analysis of Variance, Atracurium blood, Central Nervous System Agents blood, Female, Humans, Isoquinolines blood, Male, Middle Aged, Neuromuscular Nondepolarizing Agents blood, Time Factors, Vecuronium Bromide blood, Atracurium cerebrospinal fluid, Atracurium pharmacokinetics, Central Nervous System Agents cerebrospinal fluid, Central Nervous System Agents pharmacokinetics, Intracranial Aneurysm surgery, Isoquinolines cerebrospinal fluid, Isoquinolines pharmacokinetics, Neuromuscular Nondepolarizing Agents cerebrospinal fluid, Neuromuscular Nondepolarizing Agents pharmacokinetics, Subarachnoid Hemorrhage physiopathology, Vecuronium Bromide cerebrospinal fluid, Vecuronium Bromide pharmacokinetics
- Abstract
Background: Neuromuscular blocking agents may exert central nervous system effects when they reach the brain. This study assessed the concentrations and the time course of passage of vecuronium, atracurium, and its metabolite laudanosine in the cerebrospinal fluid (CSF) of patients undergoing intracranial aneurysm clipping., Methods: Twenty-five patients with subarachnoid hemorrhage were randomly allocated to receive an intravenous infusion of vecuronium (n=13) or atracurium (n=12). Arterial blood and lumbar CSF were sampled before and 1, 2, 3, 4 and 8 h after the start of the relaxant infusion. The samples were analyzed by liquid chromatography-electrospray ionization mass spectrometry (vecuronium) and high-pressure liquid chromatography (atracurium and laudanosine)., Results: The data of 20 patients (10 in both groups) were analyzed. In 11 CSF samples from five patients atracurium was detected in concentrations from 10 to 50 ng/ml. Laudanosine was retrieved in all CSF samples at 1, 2, 3, 4 and 8 h; the highest CSF concentration of laudanosine occurred at 3 h [38 (18-63) ng/ml: median (range)]. Vecuronium was not found in any CSF sample., Conclusion: Significant concentrations of atracurium and laudanosine but not of vecuronium were detected in the CSF of patients during and immediately after intracranial aneurysm surgery.
- Published
- 2002
- Full Text
- View/download PDF
238. [Neuropharmacology and receptor studies in the elderly].
- Author
-
Meltzer CC
- Subjects
- Aging pathology, Alzheimer Disease metabolism, Alzheimer Disease pathology, Atrophy, Brain diagnostic imaging, Brain growth & development, Brain metabolism, Brain pathology, Cerebrovascular Circulation, Depression metabolism, Depression pathology, Humans, Image Processing, Computer-Assisted, Ligands, Magnetic Resonance Imaging, Neurodegenerative Diseases metabolism, Neurodegenerative Diseases pathology, Neurosecretory Systems metabolism, Neurotransmitter Agents metabolism, Parkinson Disease metabolism, Parkinson Disease pathology, Radiopharmaceuticals, Receptors, Drug metabolism, Receptors, Neurotransmitter metabolism, Tomography, Emission-Computed, Tomography, Emission-Computed, Single-Photon, Aging metabolism, Central Nervous System Agents pharmacokinetics
- Abstract
Functional brain imaging has provided unique and exciting opportunities to strengthen our knowledge of the biological substrate of the aging brain and neuropsychiatric disorders. Positron emission tomography (PET) is a particularly powerful tool for quantifying the neurobiological correlates of cognition, mood and behavior. Initial PET studies of aging, psychiatric disorders and neurodegenerative disease focused primarily on generalized physiological parameters such as cerebral blood flow and metabolism, and early neuroreceptor imaging studies relied on relatively non selective markers. New, selective receptor radioligands now offer a previously inaccessible means to investigate the dynamic relationships among neurochemistry, aging and psychopathology in vivo. This approach has substantial advantages over peripheral (platelet and cerebrospinal fluid) markers, neuroendocrine challenge studies, animal models, and postmortem receptor binding assays. Advances in tracer kinetic modeling, magnetic resonance imaging (MRI) to PET registration, radiochemistry techniques, instrumentation and image processing have helped pave the way for increased emphasis on functional imaging studies of neuropsychiatric disorders of the elderly. The capability to correct PET image data for the confounding effect of cerebral atrophy permits relationships among age related brain changes and neurobiological disease mechanisms to be more accurately examined in the course of normal aging and in elderly patient populations.
- Published
- 2002
239. Pharmacodynamics and atracurium and laudanosine concentrations during a fixed continuous infusion of atracurium in mechanically ventilated patients with acute respiratory distress syndrome.
- Author
-
Lefrant JY, Farenc C, De la Coussaye JE, Muller L, Ripart J, Cuvillon P, Saissi G, and Eledjam JJ
- Subjects
- Aged, Atracurium administration & dosage, Central Nervous System Agents administration & dosage, Female, Humans, Infusions, Intravenous, Isoquinolines administration & dosage, Male, Middle Aged, Neuromuscular Blockade, Neuromuscular Nondepolarizing Agents administration & dosage, Atracurium pharmacokinetics, Central Nervous System Agents pharmacokinetics, Isoquinolines pharmacokinetics, Neuromuscular Nondepolarizing Agents pharmacokinetics, Respiration, Artificial, Respiratory Distress Syndrome therapy
- Abstract
The present study was designed to assess the pharmacodynamics and the plasma levels of atracurium and laudanosine found during a 72-hour fixed rate infusion of atracurium in acute respiratory distress syndrome patients without renal or liver failure. Nine sedated and mechanically ventilated acute respiratory distress syndrome patients without renal or liver failure were paralysed with a bolus of atracurium (1 mg x kg(-1)) followed by a 72-hour continuous infusion (1 mg x kg(-1) x h(-1)). The count of train-of-four (TOF) and TOF ratio were monitored by an accelerograph until full neuromuscular recovery (T4/T1 > or = 0.7). Atracurium and laudanosine concentrations were measured from the onset to four days after cessation of the infusion. An electroencephalogram was recorded daily. Analysis showed that TOF count was always < or = 3 until cessation of the infusion. Following cessation, neuromuscular recovery occurred between 31 and 96 minutes (median value = 45 min). The highest atracurium and laudanosine concentrations ranged from 3.3 to 5.8 microg x ml(-1) and from 3 to 20 microg x ml(-1) respectively. In four patients with renal impairment, the highest laudanosine concentration was > 10 microg x ml(-1). No seizure was recorded. A fixed infusion rate of atracurium in acute respiratory distress syndrome patients provided an effective muscle paralysis with a rapid neuromuscular recovery but can lead to accumulation of laudanosine in patients with renal impairment.
- Published
- 2002
- Full Text
- View/download PDF
240. Effects of psychotropic medications on the pediatric electrocardiogram and recommendations for monitoring.
- Author
-
Francis PD
- Subjects
- Adrenergic Agents adverse effects, Antidepressive Agents adverse effects, Antipsychotic Agents adverse effects, Central Nervous System Agents administration & dosage, Central Nervous System Agents pharmacokinetics, Central Nervous System Stimulants adverse effects, Child, Cytochrome P-450 Enzyme System metabolism, Drug Interactions, Drug Overdose, Humans, Practice Guidelines as Topic, Ventricular Dysfunction etiology, Ventricular Dysfunction prevention & control, Central Nervous System Agents adverse effects, Electrocardiography drug effects
- Abstract
Reports of sudden unexpected death in pediatric patients taking selected psychotropic drugs have raised the possibility of ventricular dysrhythmias as the cause of these deaths. The use of psychotropic drugs in the pediatric population has increased significantly in recent years with increasing reports of electrocardiogram abnormalities, particularly prolongation of the corrected QT interval. Many factors affect the susceptibility of the heart to conduction abnormalities and sudden ventricular dysrhythmias in pediatric patients taking psychotropic drugs. These complex relations include genetic predisposition, structural cardiac disease, drug-drug interactions, drug dosage, and drug metabolism and clearance. Many specific psychotropic drugs have been reported to prolong the QTc interval and increase the risk of ventricular dysrhythmias and sudden death. This article discusses the various factors that may influence the electrocardiogram in pediatric patients taking psychotropic drugs and recommendations for monitoring these patients.
- Published
- 2002
- Full Text
- View/download PDF
241. QRAR models for central nervous system drugs using biopartitioning micellar chromatography.
- Author
-
Quiñones-Torrelo C, Martin-Biosca Y, Martínez-Pla JJ, Sagrado S, Villanueva-Camañas RM, and Medina-Hernández MJ
- Subjects
- Animals, Central Nervous System Agents pharmacokinetics, Chromatography, Micellar Electrokinetic Capillary, Humans, Models, Biological, Quantitative Structure-Activity Relationship, Central Nervous System Agents chemistry, Central Nervous System Agents pharmacology
- Abstract
The capability of biopartitioning Micellar Chromatography, BMC, to describe and estimate pharmacokinetic and pharmacodynamic parameters of central nervous system drugs is reviewed in this article. BMC is a mode of micellar liquid chromatography, MLC, that uses micellar mobile phases of Brij35 (polyoxyethilene(23) lauryl ether) prepared in physiological conditions (pH, ionic strength). The retention of a drug in this system depends on its hydrophobic, electronic and steric properties, which also determine its biological activity. The results of BMC studies suggest that this in vitro approach is an attractive useful tool to be implemented into the lead optimization step of drug development scheme.
- Published
- 2002
- Full Text
- View/download PDF
242. Nanoparticle technology for drug delivery across the blood-brain barrier.
- Author
-
Lockman PR, Mumper RJ, Khan MA, and Allen DD
- Subjects
- Animals, Biological Transport physiology, Central Nervous System Agents pharmacokinetics, Humans, Blood-Brain Barrier physiology, Brain metabolism, Drug Delivery Systems methods, Nanotechnology
- Abstract
Nanoparticles (NP) are solid colloidal particles ranging in size from 1 to 1000 nm that are utilized as drug delivery agents. The use of NPs to deliver drugs to the brain across the blood-brain barrier (BBB) may provide a significant advantage to current strategies. The primary advantage of NP carrier technology is that NPs mask the blood-brain barrier limiting characteristics of the therapeutic drug molecule. Furthermore, this system may slow drug release in the brain, decreasing peripheral toxicity. This review evaluates previous strategies of brain drug delivery, discusses NP transport across the BBB, and describes primary methods of NP preparation and characterization. Further, influencing manufacturing factors (type of polymers and surfactants, NP size, and the drug molecule) are detailed in relation to movement of the drug delivery agent across the BBB. Currently, reports evaluating NPs for brain delivery have studied anesthetic and chemotherapeutic agents. These studies are reviewed for efficacy and mechanisms of transport. Physiological factors such as phagocytic activity of the reticuloendothelial system and protein opsonization may limit the amount of brain delivered drug and methods to avoid these issues are also discussed. NP technology appears to have significant promise in delivering therapeutic molecules across the BBB.
- Published
- 2002
- Full Text
- View/download PDF
243. Pharmacokinetic imaging: a noninvasive method for determining drug distribution and action.
- Author
-
Fischman AJ, Alpert NM, and Rubin RH
- Subjects
- Animals, Anti-Infective Agents pharmacokinetics, Antineoplastic Agents pharmacokinetics, Central Nervous System Agents pharmacokinetics, Drug Evaluation, Humans, Magnetic Resonance Spectroscopy, Radioactive Tracers, Radiopharmaceuticals pharmacokinetics, Tissue Distribution, Image Processing, Computer-Assisted instrumentation, Tomography, Emission-Computed
- Abstract
Advances in positron emission tomography (PET), single photon emission computed tomography (SPECT) and magnetic resonance spectroscopy (MRS), and the ability to label a wide variety of compounds for in vivo use in humans, have created a new technology for making precise physiological and pharmacological measurements. Due to the noninvasive nature of these approaches, repetitive and/or continuous measurements have become possible. Thus far, these techniques have been primarily used for one-time assessments of individuals. However, experience suggests that a major use of this technology will be in the evaluation of new drug therapies. Already, these techniques have been used to measure precisely and noninvasively the pharmacokinetics of a variety of antimicrobial, antineoplastic and CNS agents. In the case of CNS drugs, imaging techniques (particularly PET) have been used to define the classes of neuroreceptors with which the drug interacts. The physiological, pharmacological and biochemical measurements that can be performed noninvasively using modern imaging techniques can greatly facilitate the evaluation of new therapies. These measurements are most likely to be useful during drug development in preclinical studies and in phase I/II human studies. Preclinically, new drugs can be precisely compared with standard therapies, or a series of analogues can be screened for further development on the basis of performance in animal models. In Phase I/II, imaging measurements can be combined with classical pharmacokinetic data to establish optimal administration schedules, evaluate the utility of interventions in specific clinical situations, and aid in the design of Phase III trials.
- Published
- 2002
- Full Text
- View/download PDF
244. Design and synthesis of a maximally diverse and druglike screening library using REM resin methodology.
- Author
-
Barn D, Caulfield W, Cowley P, Dickins R, Bakker WI, McGuire R, Morphy JR, Rankovic Z, and Thorn M
- Subjects
- Animals, Benzylamines chemical synthesis, Benzylamines chemistry, Benzylamines pharmacokinetics, Blood-Brain Barrier, Central Nervous System Agents chemistry, Central Nervous System Agents pharmacokinetics, Chemistry, Pharmaceutical, Drug Design, Humans, Resins, Synthetic, Central Nervous System Agents chemical synthesis, Combinatorial Chemistry Techniques
- Abstract
A 3042 compound screening library was synthesized using a combination of two solid-phase technologies: REM resin methodology and Lewis acid promoted aminolysis. The exclusivity and structural diversity of the library were enhanced by using a highly divergent synthetic strategy involving 13 different scaffolds (9 of which were custom-made), five different types of resin-bound phenol derivatization chemistry (Mitsunobu, Suzuki, acylation, sulfonylation, and carbamoylation), and three different cleavage strategies (Hofmann elimination, AlCl(3)-promoted aminolysis, base-promoted esterolysis). This is the first example of a solid-phase Suzuki coupling involving a resin-bound aryl triflate being used for library synthesis. Computational analysis suggested that the compounds are likely to have favorable properties for CNS penetration. Analysis of the library by HPLC and MS suggested at least 90% of the sampled members were present in an average purity of approximately 70%. Encouragingly, hits have been identified from high-throughput screening of this library, such as compound 6, which has an affinity of 1.02 microM for the GlyT(2) transporter.
- Published
- 2001
- Full Text
- View/download PDF
245. Integration of mass spectrometry into early-phase discovery and development of central nervous system agents.
- Author
-
Prokai L, Zharikova A, Janáky T, Li X, Braddy AC, Perjési P, Matveeva L, Powell DH, and Prokai-Tatrai K
- Subjects
- Animals, Blood-Brain Barrier, Brain enzymology, Brain metabolism, Central Nervous System Agents chemistry, Central Nervous System Agents pharmacokinetics, Chromatography, Liquid, Combinatorial Chemistry Techniques, Drug Design, Extracellular Space metabolism, Indicators and Reagents, Male, Mass Spectrometry, Microdialysis, Neuropeptides chemical synthesis, Neuropeptides chemistry, Neuropeptides pharmacokinetics, Rats, Rats, Sprague-Dawley, Central Nervous System Agents chemical synthesis
- Abstract
The early-phase discovery and development of useful central nervous system (CNS) agents present ample opportunities to exploit mass spectrometry and provide detailed compound/mixture characterization, or to make the process faster and/or more economic. Neuropeptide FF antagonists and centrally active thyrotropin-releasing hormone analogues were used as specific examples in this work. We evaluated the characterization of focused libraries of peptide derivatives by electrospray ionization, tandem mass spectrometry and liquid chromatography/tandem mass spectrometry on a quadrupole ion trap and nanoelectrospray on a Fourier transform ion cyclotron resonance mass spectrometer. Immobilized artificial-membrane chromatography was employed as a model to predict/rank new agents against lead compounds for their potential to reach the central nervous system in pharmacologically significant amounts. Measuring brain concentrations in rodents after the intravenous administration of test compounds was used as an in vivo approach, and we took advantage of microdialysis sampling that furnished samples without interfering tissue matrix and afforded the estimation of extracellular concentrations in a localized part of the brain. Overall, making atmospheric-pressure ionization mass spectrometry an integral part of the process has played a major role in increasing throughput, selectivity, specificity and detection sensitivity and thereby providing useful information about the extent or mechanism of transport and metabolic activation/inactivation in early-phase discovery and development of CNS agents., (Copyright 2001 John Wiley & Sons, Ltd.)
- Published
- 2001
- Full Text
- View/download PDF
246. Progress and limitations in the use of in vitro cell cultures to serve as a permeability screen for the blood-brain barrier.
- Author
-
Gumbleton M and Audus KL
- Subjects
- Animals, Blood-Brain Barrier drug effects, Capillary Permeability drug effects, Cells, Cultured, Central Nervous System Agents pharmacokinetics, Central Nervous System Agents pharmacology, Endothelium, Vascular cytology, Endothelium, Vascular drug effects, Endothelium, Vascular physiology, Humans, Permeability drug effects, Blood-Brain Barrier physiology, Capillary Permeability physiology
- Abstract
A relatively simple, widely applicable, and robust in vitro method of predicting blood-brain barrier (BBB) permeability to central nervous system-acting drugs is an increasing need. A cell-based model offers the potential to account for transcellular and paracellular drug diffusional processes, metabolism, and active transport processes, as well as nondefined interactions between a drug and cellular material that may impact upon a membrane's overall permeability profile. Any in vitro BBB cell model to be utilized for the transendothelial BBB permeability screening of potential central nervous system drugs must display reproducible solute permeability, and a number of other general criteria including: a restrictive paracellular barrier; a physiologically realistic cell architecture; the functional expression of key transporter mechanisms; and allow ease of culture to meet the technical and time constraints of a screening program. This article reviews the range of in vitro cell-based BBB models available, including the primary/low passage bovine and porcine brain endothelial cultures as well as the spectrum of immortalized brain endothelial cell lines that have been established. The article further discusses the benefits and limitations of exploiting such systems as in vitro BBB permeability screens., (Copyright 2001 Wiley-Liss, Inc. and the American Pharmaceutical Association)
- Published
- 2001
- Full Text
- View/download PDF
247. High-throughput prediction of blood-brain partitioning: a thermodynamic approach.
- Author
-
Keserü GM and Molnár L
- Subjects
- Central Nervous System Agents chemistry, Central Nervous System Agents pharmacokinetics, Drug Evaluation, Preclinical, Models, Biological, Thermodynamics, Blood-Brain Barrier
- Abstract
A high-throughput in silico screening tool for potentially CNS active compounds was developed on the basis of the correlation of solvation free energies and blood-brain partitioning (log(cbrain/cblood) = log BB) data available from experimental sources. Utilizing a thermodynamic approach, solvation free energies were calculated by the fast and efficient generalized Born/surface area continuum solvation model, which enabled us to evaluate more than 10 compounds/min. Our training set involved a structurally diverse set of 55 compounds and yielded a function of log BB = 0.035Gsolv + 0.2592 (r = 0.85, standard error 0.37). Calculation of solvation free energies for 8700 CNS active compounds (CIPSLINE database) revealed that Gsolv is higher than -50 kJ/mol for the 96% of these compounds which can be used as suitable criteria for the identification of compounds preferable for CNS penetration.
- Published
- 2001
- Full Text
- View/download PDF
248. Evaluation of the BBMEC model for screening the CNS permeability of drugs.
- Author
-
Otis KW, Avery ML, Broward-Partin SM, Hansen DK, Behlow HW Jr, Scott DO, and Thompson TN
- Subjects
- Animals, Antineoplastic Agents, Phytogenic pharmacokinetics, Biological Transport, Caffeine pharmacokinetics, Cattle, Central Nervous System Agents pharmacokinetics, Drug Combinations, Mannitol pharmacokinetics, Microdialysis, Models, Biological, Permeability, Vinblastine pharmacokinetics, Blood-Brain Barrier, Brain blood supply, Drug Evaluation, Preclinical methods, Endothelium, Vascular metabolism
- Abstract
Combinatorial synthesis and high-throughput pharmacology screening have greatly increased compound throughput in modern drug-discovery programs. For CNS drugs, it is also important to determine permeability to the blood--brain barrier. Yet, given the increased pace of discovery, it difficult to conduct this screen in a timely fashion. In this presentation, we describe several improvements to an existing CNS permeability screen, the bovine brain microvessel endothelial cell (BBMEC) model. By implementation of these incremental process improvements, we have achieved a robust, facile screen for determination of CNS permeability of multiple compounds.
- Published
- 2001
- Full Text
- View/download PDF
249. Transporter-mediated permeation of drugs across the blood-brain barrier.
- Author
-
Tamai I and Tsuji A
- Subjects
- Animals, Anti-Infective Agents pharmacokinetics, Humans, Membrane Proteins metabolism, Monosaccharide Transport Proteins metabolism, Nucleoside Transport Proteins, Quinolones pharmacokinetics, Blood-Brain Barrier physiology, Carrier Proteins metabolism, Central Nervous System Agents pharmacokinetics, Fluoroquinolones, Ion Pumps metabolism
- Abstract
Drug distribution into the brain is strictly regulated by the presence of the blood-brain barrier (BBB) that is formed by brain capillary endothelial cells. Since the endothelial cells are connected to each other by tight junctions and lack pores and/or fenestrations, compounds must cross the membranes of the cells to enter the brain from the bloodstream. Therefore, hydrophilic compounds cannot cross the barrier in the absence of specific mechanisms such as membrane transporters or endocytosis. So, for efficient supply of hydrophilic nutrients, the BBB is equipped with membrane transport systems and some of those transporter proteins have been shown to accept drug molecules and transport them into brain. In the present review, we describe mainly the transporters that are involved in drug transfer across the BBB and have been molecularly identified. The transport systems described include transporters for amino acids, monocarboxylic acids, organic cations, hexoses, nucleosides, and peptides. Most of these transporters function in the direction of influx from blood to brain; the presence of efflux transporters from brain to blood has also been demonstrated, including P-glycoprotein, MRPs, and other unknown transporters. These efflux transporters seem to be functional for detoxication and/or prevention of nonessential compounds from entering the brain. Various drugs are transported out of the brain via such efflux transporters, resulting in the decrease of CNS side effects for drugs that have pharmacological targets in peripheral tissues or in the reduction of efficacy in CNS because of the lower delivery by efflux transport. To identify the transporters functional at the BBB and to examine the possible involvement of them in drug transports by molecular and physiological approaches will provide a rational basis for controlling drug distribution to the brain., (Copyright 2000 Wiley-Liss, Inc.)
- Published
- 2000
- Full Text
- View/download PDF
250. Recent advances in biotransformation of CNS and cardiovascular agents.
- Author
-
Wu WN and McKown LA
- Subjects
- Animals, Biotransformation, Humans, Cardiovascular Agents pharmacokinetics, Central Nervous System Agents pharmacokinetics
- Abstract
Compound biotransformation is a very important research area for drug discovery and development. In this review, publications from the metabolism studies of ten compounds, seven CNS and three cardiovascular agents, from the Johnson & Johnson Corp. were reviewed. The seven CNS compounds are: three antipsychotic agents, mazapertine (arypiperazine analog), RWJ-46344 (arypiperidine analog) and risperidone (aryisoxazole-piperidine analog), one antidepressant, etoperidone (arypiperazine analog), one anxiolytic agent, fenobam (aryimidazole urea analog), one muscle relaxant, xilobam (pyrrolidinylidene urea analog), and one antiepileptic agent, topiramate (fructopyranose sulfamate analog). The three cardiovascular agents are: two arylalkylamine calcium channel blockers, bepridil and RWJ-26240, and one thioindolaminidine antianginal agent, RWJ-34130. Other antipsychotic and antidepressant agents with similar analogs (ziprasidone, trazodone and nefazodone) as well as other similar analogs of calcium channel blockers (verapamil) are discussed. In this article, excretion and metabolism (in vitro, in vivo) of compounds are reviewed from the CNS agents to the cardiovascular agents, including structures of parent compounds, their metabolites, metabolic pathways, and methods for the isolation, profiling, quantification and structural identification of unchanged compounds and metabolites. Pharmacological activities of parent compounds and their metabolites are also briefly discussed.
- Published
- 2000
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.